Xenon Pharmaceuticals (XENE) Interest Expenses (2013 - 2020)

Xenon Pharmaceuticals (XENE) has reported Interest Expenses for 14 consecutive years, with $8.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest Expenses fell 15.05% year-over-year to $8.3 million; the TTM figure through Mar 2026 stood at $8.3 million (down 15.05% YoY), while the FY2025 annual figure was $346.8 million, up 211.86% from the prior year.
• Interest Expenses improved to $8.3 million in Q1 2026 per XENE's latest filing, from $434000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $12.7 million in Q3 2023 and bottomed at $281000.0 in Q4 2022.
• Historically, Interest Expenses has averaged $5.6 million across 5 years, with a median of $2.3 million in 2023.
• Annual changes were most pronounced in 2022 — Interest Expenses soared 1915.97% — and 2025, when it tumbled 90.96%.
• Xenon Pharmaceuticals' Interest Expenses stood at $281000.0 in 2022, then jumped by 44.13% to $405000.0 in 2023, then advanced by 5.43% to $427000.0 in 2024, then rose by 1.64% to $434000.0 in 2025, then soared by 1806.68% to $8.3 million in 2026.
• Business Quant data shows XENE's Interest Expenses at $8.3 million in Q1 2026, $434000.0 in Q4 2025, and $9.3 million in Q3 2025.